| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184449 | Gynecologic Oncology | 2014 | 8 Pages |
Abstract
ECARS validates to identify aggressive endometrial carcinomas in multiple, independent patients cohorts. The higher signature score in metastatic compared to primary lesions, and the potential link to PI3K activation and EMT, support further studies of ECARS in relation to response to PI3K and EMT inhibitors in clinical trials of metastatic endometrial carcinoma.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
E. Wik, J. Trovik, K. Kusonmano, E. Birkeland, M.B. Raeder, I. Pashtan, E.A. Hoivik, C. Krakstad, H.M.J. Werner, F. Holst, S. Mjøs, M.K. Halle, M. Mannelqvist, K.K. Mauland, A.M. Oyan, I.M. Stefansson, K. Petersen, R. Simon, H.B. Salvesen,